A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression

被引：0
|
作者：
Siegfried Kasper
Nicole Praschak-Rieder
Johannes Tauscher
Rainer Wolf
机构：
[1] University of Vienna,Department of General Psychiatry
来源：
Drug Safety | 1997年 / 17卷
关键词：
Adis International Limited; Amitriptyline; Sexual Dysfunction; Mirtazapine; Clomipramine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mirtazapine is the first of a new class of antidepressants, the noradrenergic and specific serotonergic antidepressants (NaSSA). Its antidepressant effect appears to be related to its dual enhancement of central noradrenergic and serotonin 5-HT1 receptor-mediated serotonergic neurotransmission.
引用
收藏
页码：251 / 264
页数：13
相关论文
共 50 条
  • [31] RISK-BENEFIT ASSESSMENT OF AMIODARONE IN THE TREATMENT OF CARDIAC-ARRHYTHMIAS
    COUNIHAN, PJ
    MCKENNA, WJ
    DRUG SAFETY, 1990, 5 (04) : 286 - 304
  • [32] A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia
    Ekman, P
    DRUG SAFETY, 1998, 18 (03) : 161 - 170
  • [33] RISK-BENEFIT ASSESSMENT OF DRUGS USED FOR THE TREATMENT OF MENSTRUAL DISORDERS
    HIGHAM, JM
    SHAW, RW
    DRUG SAFETY, 1991, 6 (03) : 183 - 191
  • [34] Risk-benefit assessment of ivabradine in the treatment of chronic heart failure
    Urbanek, Irmina
    Kaczmarek, Krzysztof
    Cygankiewicz, Iwona
    Ptaszynski, Pawel
    DRUG HEALTHCARE AND PATIENT SAFETY, 2014, 6 : 47 - 54
  • [35] A RISK-BENEFIT ASSESSMENT OF MOCLOBEMIDE IN THE TREATMENT OF DEPRESSIVE-DISORDERS
    NORMAN, TR
    BURROWS, GD
    DRUG SAFETY, 1995, 12 (01) : 46 - 54
  • [36] A risk-benefit assessment of tacrine in the treatment of Alzheimer's disease
    Samuels, SC
    Davis, KL
    DRUG SAFETY, 1997, 16 (01) : 66 - 77
  • [37] A Risk-Benefit Assessment of Tacrine in the Treatment of Alzheimer’s Disease
    Steven C. Samuels
    Kenneth L. Davis
    Drug Safety, 1997, 16 : 66 - 77
  • [38] A Risk-Benefit Assessment of Amifostine in Cytoprotection
    May Mabro
    Sandrine Faivre
    Eric Raymond
    Drug Safety, 1999, 21 : 367 - 387
  • [39] A Risk-Benefit Assessment of Antileukotrienes in Asthma
    Lewis J. Smith
    Drug Safety, 1998, 19 : 205 - 218
  • [40] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
12345